Transdermal Ketoprofen Patch with CHADD
Drug12 hours patch application for 28 days
Other names: Matrix Transdermal Ketoprofen/CHADD Sytem
NCT Number: NCT00108810
The purpose of the study is to evaluate the safety and effectiveness of the investigational ketoprofen patch with a controlled heating patch, compared to placebo (inactive substance) for the treatment of pain caused by osteoarthritis.
Looking for future studies?
Notify Me40 year–75 year
All sexes
Interventional
Phase 2
SouthBay Pharma Research, Buena Park, California, United States
Proof-of-concept study, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy of a transdermal ketoprofen patch with CHADD heat versus a placebo patch with dummy heat in patients with mild to moderate pain associated with osteoarthritis of the knee. After screening, patients discontinue all analgesic medication (except ≤325 mg aspirin daily for cardioprotective purposes). Patients selected a target knee (right or left), and all efficacy evaluations were completed with respect to this target knee. After discontinuing analgesics for at least 48 hours, and when the average pain intensity over the previous 24 hours for the target knee was ≥40 mm using a 100 mm visual analog scale (VAS), patients were randomized in a 1:1 fashion to receive treatment with either the transdermal ketoprofen patch with CHADD heat or the placebo patch with dummy heat. Patients treated the target knee each night for 12 hours (± 1 hour) for 4 weeks. Patients returned to the study site every 7 days (± 1 day) for study evaluations. Throughout the study, patients were allowed to take up to 2000 mg acetaminophen per day as rescue medication; however, rescue medication was not allowed within the 48 hours prior to efficacy evaluations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
12 hours patch application for 28 days
Other names: Matrix Transdermal Ketoprofen/CHADD Sytem
12 hours application for 28 days
Other names: Placebo patch with dummy heating unit
Time frame: 28 days
Time frame: 28 days
Time frame: 28 days
Patient global satisfaction score at Study Visit 5
Time frame: 28 days
ZARS Pharma Inc.
Industry
Randomized, Double-Blind, Parallel, Placebo Controlled 4 Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of Transdermal Ketoprofen When Administered With Controlled Heat in Patients With Mild to Moderate OA Pain of the Knee
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07571772
Arthritis, Behavior
Erzurum, Yakutiye, Turkey (Türkiye)
View Trial DetailsNCT05869630
Arthritis, Behavior
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05663996
Arthritis, Joint Diseases
Osmaniye, Turkey (Türkiye)
View Trial DetailsNCT00361504
Arthritis, Back Pain
Mesa, Arizona, United States
View Trial Details